STOCKS TELEGRAPH

Tag: NASD:INZY

  • Acquisition News Propels Inozyme Pharma (INZY) Shares Upward

    Acquisition News Propels Inozyme Pharma (INZY) Shares Upward

    Following the announcement of a formal acquisition deal, Inozyme Pharma, Inc. (NASDAQ: INZY) shares jumped 178.17% as of the last check today to $3.95. INZY revealed that BioMarin Pharmaceutical will buy it for all cash for about $270 million.

    Strategic Growth of BioMarin’s Portfolio of Rare Diseases

    BioMarin will buy Inozyme at a price of $4.00 per share. The deal, anticipated to finalize in the third quarter of 2025, has received unanimous approval from the boards of directors of both businesses. The purchase is in line with BioMarin’s continuous plan to expand its line of enzyme replacement treatments, especially for uncommon and serious genetic disorders.

    A Potential Treatment

    INZ-701, Inozyme’s late-stage, first-in-class enzyme replacement treatment for ENPP1 Deficiency, is at the heart of this transaction. The circulatory system, soft tissues, and skeletal structure are all impacted by this uncommon and severe genetic condition, which has a significant risk of death, particularly in newborns. Later in adulthood, patients also have osteomalacia and rickets. In addition to ongoing or planned research for babies, adolescents, and adults, INZ-701 is presently undertaking critical Phase 3 trials in pediatric populations.

    Enhancing Regulatory Routes and Clinical Development

    Initial findings from INZ-701’s adult trials have been positive, with increases in important indicators including bone mineralization and pyrophosphate levels as well as a good safety profile. Data from the pediatric Phase 3 study is anticipated in early 2026, with a possible regulatory clearance date of 2027. For patients with ENPP1 Deficiency, this places INZ-701 as a potentially ground-breaking treatment that fills a major unmet need.

    The Acquisition Process’s Next Steps

    BioMarin plans to buy all of the outstanding shares of Inozyme common stock at $4.00 a share through a cash tender offer. Any remaining shares will be purchased through a merger with a BioMarin subsidiary when the tender is over, guaranteeing INZY’s complete integration into the BioMarin company.

  • An Uptick In Inozyme (INZY) Stock After-Hours

    An Uptick In Inozyme (INZY) Stock After-Hours

    In the post-market session on Thursday, shares of Inozyme Pharma, Inc. (NASDAQ: INZY) exhibited an upward trajectory. Notably, the stock experienced a notable ascent of 7.45%, reaching a value of $3.46 during the extended trading period. In the preceding regular session, the performance of INZY stock was relatively stable, registering a modest increase of 0.62% and concluding at $3.22. The positive momentum in INZY stock was spurred by the active involvement of its leadership in a significant event.

    The Chief Executive Officer and Chairman of INZY, Dr. Douglas A. Treco, participated at The Jefferies London Healthcare Conference held recently. Additionally, the executive is slated to participate in The Piper Sandler 35th Annual Healthcare Conference, engaging in a fireside chat scheduled for Thursday, November 30, from 12:00 to 12:25 pm ET.

    Furthermore, Inozyme Pharma recently issued a comprehensive business update. The company reported the initiation of patient recruitment for the pivotal ENERGY-3 trial of INZ-701, focusing on pediatric patients with ENPP1 Deficiency. INZY is on course to unveil topline data in mid-2025. Encouraging outcomes from the phase 1/2 clinical trial of INZ-701 in adults with ENPP1 Deficiency were also disclosed.

    The ongoing trial demonstrated positive interim results in safety, pharmacokinetics (PK), pharmacodynamics (PD), and exploratory efficacy data. Notably, exploratory data indicated clinical benefits for ENPP1 Deficiency, encompassing improvements in key biomarkers, patient-reported outcomes (PROs), and functional outcomes. The Phase 2 portion of the trial is actively dosing, with the company anticipating reporting topline clinical data from the first three cohorts through 48 weeks in the first quarter of 2024.

    Similarly, the phase 1/2 clinical trial of INZ-701 in adults with ABCC6 Deficiency yielded positive interim results in safety, PK, PD, and exploratory efficacy data. All three dose cohorts exhibited improvements in the Global Impression of Change (GIC), a PRO.

    The company is on track to disclose topline clinical data through 48 weeks in the first quarter of 2024. Inozyme also unveiled plans for an oral presentation at the American Society for Nephrology (ASN) Kidney Week 2023 and intends to present three posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting.